21h
GlobalData on MSNTakeda broadens its deal with BridGene for up to $770mBridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...
The efforts over the past year by the team at Keros have positioned us to continue to advance our promising pipeline of novel therapeutics,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive ...
23h
Hosted on MSNEMA approves Takeda’s Takhzyro pre-filled pen option for HAEThe European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...
In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...
Corundum Systems Biology, an investment firm supporting early-stage companies developing biomedical solutions, hired operating partner Henry Haiser, PhD from Takeda and Rotem Gura-Sadovsky, PhD as ...
Rajiv Onat, India head, digital technology and engineering, Regeneron, acknowledged Telangana’s role in creating a ...
1h
The Jordan Times on MSNHikma Pharmaceuticals Reports 'Strong' 2024 Results With 9% Revenue GrowthAMMAN - Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 ...
The new regional registry for rare disease patients in Campania, inaugurated in January, the multidisciplinary ...
The Philippine Pediatric Society advocates for the approval of a next-generation dengue vaccine to combat the rising dengue ...
EUROPE: Trump said the EU and other countries have troubling trade surpluses with the United States. He has said the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results